Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-23 00:43 | 2025-04-21 | CNTA | Centessa Pharmaceuticals plc | SAHA SAURABH | Director, Officer | SELL | $12.39 | 55,000 | $681,577 | 221,017 |
| 2025-04-22 13:05 | 2025-04-17 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $8.98 | 5,400 | $48,492 | 5,567,002 |
| 2025-04-23 00:38 | 2024-04-30 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.16 | 197,408 | $31,585 | 78,319,787 |
| 2025-04-22 14:01 | 2025-04-17 | PEPG | PepGen Inc. | McArthur James G | Director, Officer | BUY | $1.36 | 10,000 | $13,550 | 113,913 |
| 2025-04-23 04:00 | 2025-04-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $10.22 | 100,000 | $1,022,000 | 1,116,345 |
| 2025-04-22 23:30 | 2025-04-21 | UTHR | UNITED THERAPEUTICS Corp | DWEK RAYMOND | Director | OPT+S | $285.57 | 3,000 | $856,710 | 1,750 |
| 2025-04-22 23:33 | 2025-04-22 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $38.11 | 2,000 | $76,220 | 140,255 |
| 2025-04-22 00:55 | 2025-04-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $16.42 | 5,000 | $82,096 | 985,392 |
| 2025-04-21 23:04 | 2025-04-17 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Officer | SELL | $0.98 | 108 | $106 | 370,218 |
| 2025-04-21 23:03 | 2025-04-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $0.96 | 8 | $8 | 481,702 |
| 2025-04-22 00:42 | 2025-04-21 | CYTK | CYTOKINETICS INC | WIERENGA WENDALL | Director | OPT+S | $38.46 | 20,000 | $769,200 | 24,848 |
| 2025-04-18 22:17 | 2025-04-16 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $11.32 | 128,713 | $1,456,413 | 17,828,487 |
| 2025-04-18 23:31 | 2025-04-17 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $283.78 | 11,000 | $3,121,543 | 36,781 |
| 2025-04-17 23:53 | 2025-04-16 | IONS | IONIS PHARMACEUTICALS INC | Birchler Brian | Officer | OPT+S | $28.37 | 680 | $19,292 | 56,660 |
| 2025-04-17 23:55 | 2025-04-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $68.94 | 27,000 | $1,861,504 | 249,062 |
| 2025-04-17 23:53 | 2025-04-16 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $28.40 | 3,928 | $111,555 | 31,926 |
| 2025-04-17 23:53 | 2025-04-16 | IONS | IONIS PHARMACEUTICALS INC | Jenne Kyle | Officer | OPT+S | $28.36 | 3,016 | $85,534 | 11,199 |
| 2025-04-18 00:41 | 2025-04-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $0.00 | 100,000 | $0 | 44,000 |
| 2025-04-17 13:10 | 2025-04-15 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.90 | 15,000 | $13,500 | 1,113,460 |
| 2025-04-17 00:00 | 2025-04-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $9.57 | 8,500 | $81,310 | 460,642 |
| 2025-04-17 00:06 | 2025-04-14 | LQDA | Liquidia Corp | Schundler Russell | Officer | SELL | $13.57 | 5,964 | $80,931 | 570,301 |
| 2025-04-17 00:04 | 2025-04-15 | LQDA | Liquidia Corp | Moomaw Scott | Officer | SELL | $13.57 | 3,406 | $46,219 | 214,744 |
| 2025-04-17 00:02 | 2025-04-14 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | SELL | $13.57 | 3,714 | $50,399 | 265,602 |
| 2025-04-17 01:00 | 2025-04-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | OPT+S | $37.91 | 9,073 | $343,962 | 95,034 |
| 2025-04-17 00:39 | 2025-04-14 | BBIO | BridgeBio Pharma, Inc. | Ellis Andrea | Director | OPT+S | $35.00 | 10,000 | $350,000 | 12,000 |
| 2025-04-16 23:38 | 2025-04-14 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $20.48 | 12,000 | $245,812 | 77,363 |
| 2025-04-17 00:03 | 2025-04-14 | LQDA | Liquidia Corp | Kaseta Michael | Officer | SELL | $13.57 | 8,283 | $112,400 | 396,315 |
| 2025-04-17 00:12 | 2025-04-14 | BGNE | BeOne Medicines Ltd. | Wang Xiaodong | Director | OPT+S | $242.66 | 41,760 | $10,133,594 | 0 |
| 2025-04-16 13:08 | 2025-04-15 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer | BUY | $0.91 | 7,500 | $6,821 | 320,040 |
| 2025-04-17 00:05 | 2025-04-14 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $13.57 | 14,130 | $191,744 | 1,006,420 |
| 2025-04-16 23:17 | 2025-04-15 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $70.16 | 6,830 | $479,177 | 233,924 |
| 2025-04-16 23:25 | 2025-04-15 | CYTK | CYTOKINETICS INC | HENDERSON JOHN T | Director | OPT+S | $38.66 | 3,190 | $123,325 | 66,348 |
| 2025-04-15 14:59 | 2025-04-14 | TXMD | TherapeuticsMD, Inc. | Walker Marlan D | Officer | BUY | $1.00 | 490 | $489 | 73,639 |
| 2025-04-16 04:12 | 2025-04-14 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $13.57 | 1,856 | $25,186 | 184,304 |
| 2025-04-16 03:36 | 2025-04-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | SELL | $12.06 | 10,757 | $129,684 | 215,340 |
| 2025-04-16 03:39 | 2025-04-14 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $14.53 | 11,366 | $165,185 | 111,686 |
| 2025-04-16 03:33 | 2025-04-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $12.19 | 15,319 | $186,803 | 862,289 |
| 2025-04-15 23:31 | 2025-04-14 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Officer | OPT+S | $25.09 | 16,723 | $419,570 | 15,625 |
| 2025-04-16 00:30 | 2025-03-31 | ASMB | Assembly Biosciences Inc. | McHutchison John G | Director | SELL | $9.85 | 757 | $7,455 | 18,347 |
| 2025-04-15 19:50 | 2025-04-02 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.56 | 28,731 | $15,966 | 1,020,300 |
| 2025-04-15 19:46 | 2025-03-26 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.60 | 123,365 | $74,525 | 991,569 |
| 2025-04-15 19:40 | 2025-03-18 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.62 | 49,927 | $30,720 | 868,204 |
| 2025-04-15 19:30 | 2025-03-10 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.62 | 64,175 | $39,506 | 818,277 |
| 2025-04-15 19:22 | 2025-02-25 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.61 | 48,930 | $29,857 | 754,102 |
| 2025-04-15 19:18 | 2025-02-03 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.66 | 84,487 | $55,525 | 705,172 |
| 2025-04-15 19:11 | 2025-01-27 | NBY | NovaBay Pharmaceuticals, Inc. | POPLAR POINT CAPITAL PARTNERS LP | 10% owner | BUY | $0.66 | 102,388 | $67,699 | 620,685 |
| 2025-04-15 14:59 | 2025-04-14 | TXMD | TherapeuticsMD, Inc. | Thompson Tommy G | Director | BUY | $1.00 | 325 | $326 | 14,779 |
| 2025-04-15 23:28 | 2025-04-14 | UTHR | UNITED THERAPEUTICS Corp | DWEK RAYMOND | Director | OPT+S | $285.16 | 3,000 | $855,480 | 1,750 |
| 2025-04-15 21:02 | 2025-04-10 | RMTI | ROCKWELL MEDICAL, INC. | Irrevocable Larson Family Investment Trust | 10% owner | BUY | $1.07 | 87,500 | $94,019 | 3,557,500 |
| 2025-04-14 13:30 | 2025-04-11 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.80 | 20,000 | $16,000 | 1,098,460 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.